Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists
Abstract
Objective Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in lipoprotein lipase, resulting in accumulation of chylomicrons in plasma and hypertriglyceridemia. Elevated triglycerides cause several complications in patients, the most serious being episodes of acute pancreatitis. This review focuses on expert guidance and opinion from an experienced lipidologist and endocrinologist as well as a current review of the literature, as there are no specific guidelines on FCS. Methods Discussion of expert guidance and opinion review of current literature. Results To date, there is no pharmacologic treatment for affected patients, and management options primarily include adoption of an extremely restricted, very-low-fat diet, along with avoidance of certain medications and alcohol. Endocrinologists often diagnose and manage patients with metabolic disorders, including patients with high triglyceride levels, but rare diseases like FCS can be missed or poorly evaluated due to knowledge gaps about disease state. Given endocrinologists' role in the treatment of lipid disorders, it is important that they understand the clinical signs and symptoms of FCS to correctly diagnose patients. Patients with FCS can be identified based on a defined clinical criteria and a thorough review of medical history, after excluding differential diagnoses and secondary factors. Typical manifestations include hypertriglyceridemia characterized by lipemic serum,…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In familial chylomicronemia syndrome, standard lipid-lowering therapies such as fibrates and omega-3 fatty acids are largely ineffective, and statins often fail to achieve adequate triglyceride reduction.
“The absence of LPL activity renders standard lipid-lowering therapies—such as fibrates and omega-3 fatty acids—largely ineffective. Similarly, statins often fail to achieve adequate TG reduction in these patients.”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [5]
Familial chylomicronemia syndrome is caused by loss-of-function mutations in the lipoprotein lipase gene, leading to triglyceride levels often exceeding 880 mg/dL.
“Among genetic forms, familial chylomicronemia syndrome (FCS) is particularly severe, caused by loss-of-function mutations in the lipoprotein lipase (LPL) gene, leading to triglyceride levels often exceeding 880 mg/dL [5, 6].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [5]
Currently available therapies are not effective enough to reach guideline-recommended therapeutic goals in acquired severe hypertriglyceridemia.
“Moreover, currently available therapies haven’t been effective enough to reach guideline-recommended therapeutic goals in acquired severe hypertriglyceridemia [5, 7, 8].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [5]
The citation lists haven’t been fetched yet
References 63 · Cited by 93
- Authors
- Falko, J. M.
- Corresponding author
- Falko, James M.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 24
- Issue
- 8
- Pages
- 756-763
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2891200332
- Cited by
- 93
- References
- 63
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 15 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 11 · 2019: 6
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- familial chylomicronemia syndrome, lipoprotein lipase deficiency, hypertriglyceridemia, chylomicrons, acute pancreatitis, very low-fat diet, underdiagnosis, diagnosis, apolipoprotein C-III, antisense therapy
- MeSH terms
- Alcoholism, Diabetes Mellitus, Diagnosis, Differential, Endocrinology, Hepatomegaly, Humans, Hypothyroidism, Lipoprotein Lipase, Hyperlipoproteinemia Type I, Nephrotic Syndrome, Pancreatitis, Plasmapheresis, Quality of Life, Recurrence, Splenomegaly, Xanthomatosis, Hypertriglyceridemia, Genetic Therapy, Abdominal Pain, Cost of Illness, Diet, Fat-Restricted, Alcohol Abstinence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review